Gene Therapy And The UK's Therexsys

8 January 1996

Human gene therapy has progressed from speculation to reality in a short space of time. In the USA a number of companies have initiated gene therapy research and development programs, and have made considerable advances.

Interest in gene therapy is reflected by a high level of media coverage. Recently, a conference in Brussels attempted to address key issues in gene therapy, such as who will benefit, when will the universal therapy be available, what will the market size be in 2010, etc. The interest in gene therapy can also be measured by the fact that it has entered public consciousness.

However, despite this interest there is only one company actively engaging in gene therapy in the UK. This is Therexsys, which was founded in July 1992 with the backing of the Medical Research Council and the Cancer Research Campaign. It is located on the Keele University Science Park at the centre of the University campus, with access to all academic and research facilities. Initial funding was completed in 1993 and raised over L6.4 million ($9.95 million) in venture capital to support in-house R&D activities and to progress products into early clinical trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight